Results 21 to 30 of about 209,966 (285)

Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis [PDF]

, 2012
Extracellular matrix deposition and tissue scarring characterize the process of fibrosis. Transforming growth factor beta (TGFβ) and Insulin-like growth factor binding protein-3 (IGFBP-3) have been implicated in the pathogenesis of fibrosis in various ...
Adriana T. Larregina, Carol A. Feghali-Bostwick, Joseph M. Pilewski, Logan R. Mlakar, Sebastien Fuchs, Ximena D. Ruiz, Yukie Yamaguchi, Yunyun Su   +7 more
core   +17 more sources

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review

International Journal of Molecular Sciences, 2023
Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide.
F. Amati, Anna Stainer, Veronica Polelli, M. Mantero, A. Gramegna, F. Blasi, S. Aliberti   +6 more
semanticscholar   +1 more source

Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial [PDF]

, 2020
Compelling data have linked disease progression in patients with idiopathic pulmonary fibrosis (IPF) with lung dysbiosis and the resulting dysregulated local and systemic immune response.
A Mishra, AW Brown, B Ley, BA Karimi-Shah, BT Baxter, CJ Ryerson, DG Pankratz, DJ Lederer, G Raghu, G Raghu, H Scheper, HR Collard, J Andrade, J Coast, J Coast, K Loudon, K Loudon, KA Getz, KD Brandt, KE Thorpe, KF Schulz, L Richeldi, L Shulgina, LB Krupp, M Fralick, M Hammond, MA Fischl, MA Perazella, MO Paterniti, MT Durheim, P Bhattacharyya, PL Molyneaux, PL Molyneaux, PL Molyneaux, R Dal-Ré, RM Califf, RM du Bois, SD Nathan, SS Birring, T Katsuyama, TE King Jr, VA Varney, WS Jones, Y Huang   +43 more
core   +1 more source

Machine learning identified MDK score has prognostic value for idiopathic pulmonary fibrosis based on integrated bulk and single cell expression data

Frontiers in Genetics, 2023
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease that poses a significant challenge to medical professionals due to its increasing incidence and prevalence coupled with the limited understanding of its underlying molecular ...
Shichen Zhang, Lanlan Zhang, Lu Wang, Hongqiu Wang, Jiaxin Wu, Haoyang Cai, Chunheng Mo, Jian Yang   +7 more
doaj   +1 more source

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management. [PDF]

, 2017
Idiopathic pulmonary fibrosis (IPF), a fibrosing interstitial pneumonia of unknown etiology, primarily affects older adults and leads to a progressive decline in lung function and quality of life.
Collard, Harold R, Oldham, Justin M
core   +2 more sources

Cellular and Molecular Mechanisms in Idiopathic Pulmonary Fibrosis

Advances in Respiratory Medicine, 2023
Highlights What are the main findings? We reviewed the latest advances in aberrant molecular events and pathological alterations in different cell populations in idiopathic pulmonary fibrosis.
Yihang Zhang, Jiazhen Wang
semanticscholar   +1 more source

Development and applicability of a dignity‐centred palliative care programme for people with idiopathic pulmonary fibrosis: A qualitative‐driven mixed methods study

Nursing Open, 2023
Aims This study evaluated the acceptability of a dignity‐centred palliative care programme for people with idiopathic pulmonary fibrosis by converging perceptions of living with idiopathic pulmonary fibrosis qualitative data and quantitative data. Design
Yasuko Igai, Sarah E. Porter
doaj   +1 more source

Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique. [PDF]

, 2015
© 2015, The Author(s).Introduction: There is a lack of agreed and established guidelines for the treatment of acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF).
Bennett, BM, Hoyles, RK, Maher, TM, Mathieson, N, Ochiai, Y, Parfrey, H, Turnbull, A, Whyte, MK, Williamson, N   +8 more
core   +2 more sources

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.

New England Journal of Medicine, 2022
BACKGROUND Phosphodiesterase 4 (PDE4) inhibition is associated with antiinflammatory and antifibrotic effects that may be beneficial in patients with idiopathic pulmonary fibrosis.
L. Richeldi, A. Azuma, V. Cottin, C. Hesslinger, S. Stowasser, C. Valenzuela, M. Wijsenbeek, D. Zoz, F. Voß, T. Maher   +9 more
semanticscholar   +1 more source

Imaging in idiopathic pulmonary fibrosis: diagnosis and mimics

Clinics, 2019
Idiopathic pulmonary fibrosis is a chronic disease of unknown etiology that usually has a progressive course and is commonly associated with a poor prognosis. The main symptoms of idiopathic pulmonary fibrosis, including progressive dyspnea and dry cough,
Bruno Hochhegger, Edson Marchiori, Matheus Zanon, Adalberto Sperb Rubin, Renata Fragomeni, Stephan Altmayer, Carlos Roberto Ribeiro Carvalho, Bruno Guedes Baldi   +7 more
doaj   +1 more source